SPOTLIGHT

NICE has given Bayer’s advanced liver cancer therapy Stivarga (regorafenib) the go-ahead after it undertook a rapid review following earlier guidance that rejected the drug. The medicine is for adults in England and Wales whose liver is well functioning but unable to be surgically removed and ...